To include your compound in the COVID-19 Resource Center, submit it here.

Merus grants Simcere exclusive Chinese rights to bispecific antibodies

Merus N.V. (NASDAQ:MRUS) granted Simcere Pharmaceutical Group (Nanjing, China) exclusive rights in China

Read the full 134 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE